FDA Posts Class I Designations For Multiple Medtronic Device Actions

Federal filings and company notices dating from 2023 through 2025 show a string of Medtronic field actions and recalls carrying the highest FDA classification for potential risk to health. Regulators, health systems and market participants have been monitoring the developments as public postings and database entries surfaced with varying timelines and device types.

Medtronic disclosed a voluntary field action affecting its MiniMed 600 series and 700 series insulin pumps in an October 4, 2024 announcement, saying the action began July 31, 2024 after customer reports of shortened battery life. In FDA adverse event records, Medtronic logged 170 reports of hyperglycemia with glucose values above 400 mg per deciliter and 11 reports of diabetic ketoacidosis in the United States from January 2023 through September 2024 that were described as potentially related to the battery issue. The company advised pump users to follow their devices built in alerts and alarms for battery status and to contact Medtronic if they observed changes in battery life.

Cardiac implantable devices have also figured prominently in the filings. Industry coverage in December 2024 noted an FDA update listing a Class I designation for a Medtronic field action affecting certain cardiac catheter products. Separately, in July 2023 the FDA categorized a recall of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators as Class I after reports of failure to deliver high voltage therapy in some devices. That July 2023 action was described in regulatory summaries as the largest FDA Class I recall of those device types to date because of the potential for life threatening outcomes if therapy is not delivered.

Most recently, an Urgent Medical Device Correction notice to consignees dated October 20, 2025 appears in the FDA AccessData database. The text of the database entry instructs recipients not to open, handle or use the affected product, to wear appropriate protective clothing when reviewing inventory, and to contact a Medtronic field representative for questions. The record lists 3,850 units in commerce and describes distribution across the United States including Hawaii and New York. The entry is filed as a Total Product Life Cycle device report and references a 510k product code of JBP. The database language cautions that records are created when a firm initiates correction or removal and that causes and classifications may be updated as investigations continue.

These parallel actions across device categories raise immediate public health and operational concerns. Clinicians and hospitals must triage patients who depend on affected devices while maintaining supplies and backup options. Patients with limited resources face particular risk if device failures lead to emergencies that are costly or logistically difficult to manage. Financial and market effects are being watched but are not quantified in public filings.

Regulatory materials also reflect broader post market activity for Medtronic products, including multiple corrective actions for deep brain stimulation and spinal cord stimulation therapies and a 2015 premarket supplement tied to a range of serious adverse events. For clinicians, patients and policymakers the pressing needs are clear. Regulators and the company must accelerate disclosure of lot numbers and linkage analyses, ensure timely replacement and coverage pathways for affected patients, and target outreach to communities that lack reliable access to emergency care. Transparency and concrete support will determine whether the public health response reduces harm equitably as investigations continue.